Study Summary
For micro residual disease (MRD) positive patients who have undergone at least 2 cycles chemotherapies for their CD19+ B-cell malignancies, there would be much more risks for them to receive hematological stem cell transplantation (HSCT) than MRD- patients. In order to reduce HSCT-related adverse events for these kind of patients, investigators plan to conduct CAR-T therapies on them first to make them achieve MRD- statuses, and then transfer them to HSCT.
Want to learn more about this trial?
Request More InfoInterventions
Second generation CAR-T cellsGENETIC
Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
Hematological stem cell transplantationPROCEDURE
Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | China |